Keep it real
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The testing could have been finished months ago and we would not know. There is no requirement to publish the results, either positive or negative. Absent a negative PR does not necessarily equate a positive test result.
Why now when we are supposed to get BIIB-millions?
So the assumption is that Anavex and Missling are in the driver seat and dictate the conditions to big pharma?
Really?
The only thing I remember from that SA article is that the author was short and therefore had plenty to gain from talking down the stock.
Congrats to those who called today as the patent-PR-day!
Thanks for clarifying.
I have read claims before on this board that Wilson would have been out by this week thanks to connections to the BOD. Seems they have not materialized, probably because those connections are non-existent. No idea what the execution problems are as 3 phase-2 trials are running and more to come.
I fully agree with the assessment regarding the potential of TPIV.
From time to time I do due dillegence and go through the company website. Came across this presentation from August 23d 2017:
https://tapimmune.com/wp-content/uploads/2017/08/TapImmune-IR-Deck-2017-08-23.pdf
Page 15...
I don't think the milestones have changed in between August 23d and August 31st...
Comparing milestones reveals no change, no delay, no deletion, no nothing...
Milestones defined on August 25th 2017
2Q 2017: On track to achieve 50% enrollment in ongoing Phase 2 dosing study of TPIV 200 for treating triple-negative breast cancer (TNBC)
3Q 2017: Publish long-term safety, immune response and survival data from completed Phase 1 clinical study of TPIV 200
3Q 2017: Report interim results from ongoing Phase 2 study of TPIV 200 in combination with AstraZeneca's durvalumab in patients with platinum-resistant ovarian cancer
3Q 2017: Mayo Clinic to initiate 280-patient Phase 2 study of TPIV 200 in women with advanced triple-negative breast cancer
3Q 2017: On track to complete enrollment in Phase 2 dosing study of TPIV 200 in TNBC
4Q 2017: TPIV 100/110 File amended IND; initate phase 1b/2 HER2/neu + breast cancer study
4Q 2017/1Q 2018- TPIV100/110 Mayo Clinic to initate Phase 1b/2 HER2/nue + DCIS study
Year end 2017: File amended investigational new drug application (IND) for TPIV 110 for treating HER2/neu+ breast cancer.
Milestones defines on June 1st 2017
2Q 2017: On track to achieve 50% enrollment in ongoing Phase 2 dosing study of TPIV 200 for treating triple-negative breast cancer (TNBC)
3Q 2017: Publish long-term safety, immune response and survival data from completed Phase 1 clinical study of TPIV 200
3Q 2017: Report interim results from ongoing Phase 2 study of TPIV 200 in combination with AstraZeneca's durvalumab in patients with platinum-resistant ovarian cancer
3Q 2017: Mayo Clinic to initiate 280-patient Phase 2 study of TPIV 200 in women with advanced triple-negative breast cancer
4Q 2017: On track to complete enrollment in Phase 2 dosing study of TPIV 200 in TNBC
Year end 2017: File amended investigational new drug application (IND) for TPIV 110 for treating HER2/neu+ breast cancer.
It's not like this is a FDA hold or something. It is actually quite smart from a business perspective: at 50% recruitment check if it meets your expectations before going to 100% enrollment.
Yes: with data.
Reason why the phase 2 trial was expanded from 80 to 120 patients:
"... patients in the second remission were seen as the next target for a creative approach. Patients in the first remission were not yet seen as available for a novel technology. And this was still considered to be a novel technology. Given that we’ve got a lot of experience now with the TNBC subpopulation, we have an opportunity to go into this healthier population in first remission. And so we’ve essentially flipped into a space that both has no other medications available during that first remission and can benefit from having a larger population that has a healthier substrate.
So we expect great things actually from that study. And the PIs, we talked a lot with the PIs in making this change and they are very excited about the opportunities that sort of presented themselves with this."
Reason why full phase 1 data is not yet available:
"A manuscript is ready to go for submission to a peer-review journal. And soon as it’s accepted it's in electronic form we will make the data available to all our shareholders."
What is different compared to your milestone list from Aug 21st?
I see no change.
Looks familiar, I have read this before.
Time will tell I guess
But Klamer will not be the one announcing anything.
Anavex was already publicly trading on the OTC so an initial public offering was no longer an option.
That's why he went to NASDAQ because big money mostly is not allowed to buy an OTC stock.
I am not the one claiming retailers are really important to the company. I belief rather the opposite that big tutes is what Missling is after.
So you can do an "initial public offering" multiple times now?
I wonder why it got the adjective "initial"
Which retailers in what driving seat??
Perhaps he posts here in disguise to keep up the retailer moral during the eternal silence??
Because tutes are mostly not allowed to buy on the OTC. And IPO is only for privately owned companies, so not an option.
You would expect him to care more if they were purchased with his own money.
Got those 1 million shares for free
Or Biogen was not impressed and discarded 2-73
You think Missling cares about retailers?? The shareholders he wants are big institutional holders, they are a lot less emotional, high maintenance and whimsy then retailers on message boards.
And the trials are ongoing. This is the quiet period were they are collecting data. Not much one can do except let the trial run its course.
No worries, with those links to the BOD, he will surely be fired later this week. After all thats the prophecy I have been reading on this board every single day.
I'll be happy to be back at 8! Then one step at a time.
Why extend a drug trial if it doesn't work?
Do you remember a PR or SEC filling promising "a big announcement" this week?
I don't !!
Now thats just a little premature. ;)
Several phase 2 trials are running. We are in an intermediate quiet period awaiting interim data.
Thanks for highlighting TPIV's profile again today, and yesterday, and the day before and,....
Why did I miss out?
Premature conclusion. Come back when the larger trial confirmz it.
How nice it is to have a direct link to the BOD and have the power to get the CEO removed!
But still PK/PD
By the way, just removing a milestone without any explenation is not OK!
Still stated as 2017 milestones:
Phase 2a – Updates on 104 week extension Alzheimer’s study
Phase 2a – Report PK/PD data
Little correction: dr Missling has been talking about PK-PD since Novenber 2015
Now that's a first when reporting on TPIV ;)